Aktuellt
SENASTE
Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sedana Medical. Our estimate changes do not affect our US estimates, which make up a large chunk of the fundamental value. Hence, we only make small changes to our fair value range.
LÄS MER
